A detailed history of Financial Gravity Companies, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Financial Gravity Companies, Inc. holds 100 shares of APLS stock, worth $3,296. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Holding current value
$3,296
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $2,884 - $4,115
100 New
100 $2.88 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.62B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Financial Gravity Companies, Inc. Portfolio

Follow Financial Gravity Companies, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Gravity Companies, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Gravity Companies, Inc. with notifications on news.